If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Sales and Marketing » New Product Development and Launch » Planning and Coordinating Launch » Communication Activities
Download FREE Excerpt
16 Info Graphics
3 Data Graphics
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
When it was approved in March 2013, Tecfidera was the third oral drug for relapse remitting multiple sclerosis (MS). Yet Biogen's Tecfidera outperformed all other MS drugs in its first three months on the market. In its first four quarters on the market, Tecfidera generated $1.4 billion in sales.
While Tecfidera's efficacy was comparable to its competitors, the new drug's safety profile was considered superior. Biogen used that advantage and also strategically priced Tecfidera so it was less than its main competitor Gilenya but more than the less popular Anbagio. This case study examines how Biogen used safety and pricing to differentiate Tecfidera from competitors and catapult the MS drug to blockbuster status.
Biotech; Manufacturing; Health Care; Pharmaceutical; Biopharmaceutical; Clinical Research; Laboratories
Biogen; Sanofi; Novartis